Picture of Veracyte logo

VCYT — Veracyte News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Veracyte Inc expected to post a loss of 25 cents a share - Earnings Preview

* Veracyte Inc  VCYT.OQ   VCYT.O  is expected to show a rise in
quarterly revenue when it reports results on July 29. 
* The South San Francisco, California-based company is expected
to report   a 132.1% increase in revenue to $48.062 million from
$20.7 million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Veracyte Inc is for a
loss of 25 cents per share. For the same quarter last year, the
company reported a loss of 22 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Veracyte Inc is
$55​, about 32.4% above​ its last closing price of $37.20. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.12       -0.12      -0.11     Beat    8.3
 Dec. 31 2020  -0.10       -0.11      -0.14     Missed  -30.2
 Sep. 30 2020  -0.20       -0.21      -0.08     Beat    61.9​
 Jun. 30 2020  -0.27       -0.24      -0.22     Beat    9.8
 Mar.          -0.19​      -0.20      -0.24     Missed  -22​
 31​ 2020​                                              
 Dec. 31 2019  -0.07       -0.07      -0.15     Missed  -100​
 Sep. 30 2019  -0.07       -0.07      -0.02     Beat    72.7
 Jun. 30 2019  -0.09       -0.10      -0.05     Beat    49
 This summary was machine generated July 27 at 21:33 GMT.  All
figures in US dollars unless otherwise stated

Recent news on Veracyte

See all news